Skip Navigation: Skip to contents

ICDM 2018

REGISTER
My Page
- Sign up
- Login

Main symposia

S2 Comorbidities of T2DM : Update of multifactorial management for comorbidities of T2DM	09:00~10:40 / Friday 12 October Convention hall A Chairman: Kun Ho Yoon, Linong Ji	Overview
Organizers: Sung Hee Choi, Sang Soo Kim This session entitled with 'comorbidites of T2DM' is clinical session and designed to provide a place for clinicians to discuss the evidences of preventing and managing cardiovascular comorbidities in patients with T2DM. In this session, the multifactorial strategy for management of comorbidities in patients of T2DM, including dyslipidemia, hypertension and increased platelet aggregation, will be presented and discussed. This session will give a comprehensive and effective multifactorial approach ensuring maximum benefit for patients with T2DM.
Hertzel C. Gerstein McMaster University, Canada	S2-1 Preventing serious health consequences of type 2 diabetes - the evidence
Sung Hee Choi Seoul National University, Korea	S2-2 Current recommendations for the treatment of dyslipidemia in T2DM
Joong-Wha Chung Chosun University, Korea	S2-3 Hypertension update: current guidelines
Young-Hoon Jeong Gyeongsang National University, Korea	S2-4 Anti-platelet therapy

S7 Benefit and harm of anti-diabetic agent : Multifaced beneficial and harmful effects of anti-diabetic agent	13:20~15:20 / Friday 12 October Convention hall A Chairman: Moon-Kyu Lee, Robert A Ritzel	Overview
Organizers: Sang Yong Kim, Cheol-Young Park This session entitled with 'benefit and harm of anti-diabetic agents' is clinical session and designed to provide a place for clinicians and basic researchers to elucidate the mechanism, efficacy and side effect of anti-diabetic agents. Despite the pharmacotherapy is essential component for treatment of diabetes, It is like a double-edged sword when used without knowing it exactly. In this session, four lecturer give a talk about the various data from pharmacokinetics to clinical benefit and harm of each class of anti-diabetic agents. Through this session, we hope that many clinicians will have the opportunity to learn more about the knowledge and appropriate use of anti-diabetic agents.
Toshimasa Yamauchi University of Tokyo, Japan	S7-1 TZD’s benefits and side effects and about the new PPAR enhancing agents to avoid those side effects
Mark E Cooper Monash University, Australia	S7-2 Benefit and harm of anti-diabetic agent: DPP4 inhibitors
Paolo Pozzilli University Campus Bio-Medico, Italy	S7-3 GLP-1 RA more benefits than harm
Ofri Mosenzon Hadassah Hebrew University, Israel	S7-4 SGLT-2 inhibitors

S13 Diabetes and gut : Diabetes and gut	09:00~11:00 / Saturday 13 October Convention hall A Chairman: Yeon Ah Sung, Philipp E. Scherer	Overview
Organizers: Jung Hyun Noh, In-Kyung Jeong This session entitled with 'diabetes and gut' is translational session and organized to provide deep insight for clinicians and basic researchers to understand the important factors of the gastrointestinal tract for glucose regulation in humans. This session consists of overview of the role of gut in glucose homeostasis, special lectures on incretin hormone, bile acid metabolism, gut microbiota, and the metabolic effect of bariatric surgery. This session will be very helpful for better understanding the underlying pathophysiology and planning the therapeutic strategies for T2DM.
Myung-Shik Lee Yonsei University, Korea	S13-1 Diabetes and gut, overview of the interplay
Young Min Cho Seoul National University, Korea	S13-2 The role of incretin in the glucose homeostasis
John Chiang Northeast Ohio Medical University, USA	S13-3 Activation of bile acid receptor signaling shapes the gut microbiota to improve diabetes and fatty liver disease
Soo Min Ahn Hallym University, Korea	S13-4 Metabolic surgery of the gut for diabetes

S17 Hypoglycemia : Clinical re-establishment of hypoglycemia	14:30~16:30 / Saturday 13 October Convention hall A Chairman: Jeong Taek Woo, Robert A. Harris	Overview
Organizers: Jung Hyun Noh, In-Kyung Jeong This session entitled with 'Clinical re-establishment of hypoglycemia' is a clinical session designed to provide a place for clinicians and diabetes educators. In this session, an update of adverse clinical outcomes of hypoglycemia will be presented, and a variety of strategies for preventing hypoglycemia including control of glycemic variability, new drugs with less hypoglycemia and way to overcome hypoglycemia unawareness will be introduced and discussed. This session will provide an updated treatment strategy to avoid hypoglycemia for your diabetic patients.
Seung-Hyun Ko The Catholic University of Korea, Korea	S17-1 Hypoglycemia and CVD outcome
Jae Hyeon Kim Sungkyunkwan University, Korea	S17-2 Control of glycemic variability for reducing hypoglycemia
Robert A Ritzel Munich Schwabing Hospital, Germany	S17-3 Treatment strategy for avoiding hypoglycemia
Hyun Min Kim Chung-Ang University, Korea	S17-4 Overcome of hypoglcemia unawareness